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           B cells undergo a random process of V(D)J re-
combination to generate the many distinct re-
ceptors needed to recognize a vast array of 
antigens. An inevitable consequence of this 
random process is the production of autoreac-
tive B cells (  1  ). An important mechanism for 
tolerizing autoreactive B cells is receptor edit-
ing (  2  ). Receptor editing results in the altera-
tion of B cell receptor specifi  city and is achieved 
by ongoing Ig gene rearrangement, most com-
monly at the light chain loci (  3  –  5  ). Light chain 
rearrangement proceeds in an ordered fashion 
as B cells develop in the bone marrow, with      
genes recombining fi  rst, followed by rearrange-
ment of the recombining sequence (RS) and      
(  6, 7  ). The RS (also known as the      deleting 
element [KDE] in humans) is a noncoding gene 
segment located 25 kb downstream of C     in 
the      locus that is rearranged during continued 
Ig light chain gene rearrangement (  8, 9  ). 
  Because of the unique structure of the      
locus, primary V    -J     rearrangements that are 
nonfunctional or autoreactive can be replaced 
via   “  leap-frogging  ”   recombination of unrear-
ranged upstream V     and downstream J     gene 
segments to form new      light chains (  Fig. 1 a  ).   
Additional rearrangement attempts can be made 
through recombination at the second      allele 
or at     . Recombination of RS to upstream 
V     gene segments or a recombination signal 
sequence within the J    -C     intron results in 
the deletion or inversion of C     and functional 
inactivation of the      locus (  Fig. 1 a  ). Because 
RS rearrangements do not encode any func-
tional proteins (  10  ), monitoring RS rearrange-
ment provides a specifi  city-independent means 
of measuring repeated rearrangement attempts 
at      (receptor editing). 
  The original studies characterizing RS re-
combination postulated that it served to promote 
     rearrangement by either repressing      rear-
rangement or activating the      locus (  7, 11  ). 
However,     -expressing B cells can form without 
undergoing RS rearrangement, indicating that 
RS is not required for the production of      (  12  ). 
When RS rearrangement is prevented in RS 
knockout mice, receptor editing is ineffi   cient 
and autoreactive B cells are found among pe-
ripheral cells (  13  ), highlighting the potential role 
of RS in establishing central tolerance and re-
ducing light chain allelic and isotypic inclusion. 
  Current clinical assays that evaluate B lym-
phocyte tolerance focus on serum autoanti-
bodies, which are products of mature B cells. 
Because secreted autoantibodies are an end 
product rather than an intermediate, they do not 
distinguish between autoimmunity that arose 
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sulin (in T1D) (  15  ). Furthermore, B cell defi  ciency or deple-
tion in mouse models ameliorates or prevents disease (  16  –  20  ). 
The results with B cell depletion therapy in humans are equiv-
ocal for SLE (EXPLORER study, available at http://www
.clinicaltrials.gov under identifi  er no. NCT00137969) and not 
yet fully explored in T1D. In this paper, we describe the status 
of central tolerance in individuals with SLE or T1D using RS 
rearrangement frequency as a marker. 
    RESULTS   
  A novel assay for estimating levels of receptor editing 
  We focused on RS rearrangement as an assay for receptor 
editing because RS rearrangement is known to accompany 
extensive light chain rearrangement during primary B cell 
maturation (  11, 21  ), and the major RS rearrangement prod-
ucts are defi  ned and share a common DNA sequence (  22  ). 
during primary B cell maturation or later because of events 
such as somatic mutation. The distinction is important because 
a defect in primary B cell tolerance may predict disease devel-
opment. Furthermore, diseases occurring as a result of a pri-
mary B cell tolerance defect may be associated with resistance 
to B cell  –  targeted therapy because the primary repertoire is 
predicted to rapidly repopulate with autoreactive cells if B cell 
reconstitution is allowed to proceed. Before testing those ideas, 
an assay for central B cell tolerance is needed. 
  This manuscript describes the development and initial 
characterization of RS rearrangement frequency as an assay for 
central B cell tolerance in systemic lupus erythematosus (SLE) 
and type 1 diabetes (T1D). In both of these diseases, B cells 
play a critical pathogenic role. Autoantibodies are a prominent 
feature, whether they be directed against nuclear antigens (in 
SLE) (  14  ), or pancreatic     -cell antigens such as GAD65 or in-
    Figure 1.         RS rearrangement is a marker of extensive      light chain rearrangement.   (a) Schematic of the mouse      light chain locus illustrating 
successive V   -J    rearrangements followed by RS rearrangement. Two pathways of RS rearrangement are available. The fi  rst (1) involves recombination of 
an upstream unrearranged V     gene segment to RS, whereas the second (2) utilizes a noncanonical recombination signal sequence (iRS) in the J   -C   
intron to rearrange to RS. Both result in the deletion of C     and functional inactivation of the Ig     locus. Exons are indicated by boxes, recombination sig-
nals are indicated by triangles, and dashed lines with arrows illustrate the rearrangements. (b) RS rearrangement levels as measured in Ig    +   (gray  bars) 
and Ig          (presumed to be     +  ; black bars) from splenic B220  +   IgM +   B cells of adult (3  –  4-mo-old) C57BL/6 mice (  n   = 5) and CD19  +   9G4       peripheral B cells 
from healthy control subjects (  n   = 26). All PCR reactions were performed in duplicate. Mouse data are presented as the fold difference relative to the 
mean RS level in C57BL/6 splenic B220  +   IgM +   Ig   +   B cells (+SEM). Human data are depicted as rearrangement frequency per genome copy (+SEM).     JEM VOL. 205, December 22, 2008 
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fraction (Fr.) D cells (small pre  –  B II cells [  28  ]), which are cy-
toplasmic Ig      +   but no longer express surrogate light chain. 
Fr. D cells express the Rag1 and Rag2 proteins for light chain 
gene rearrangement (  Fig. 2 a  ) (  28  ).   Further subsetting within 
Fr. D based upon BP-1 (aminopeptidase A) (BP-1) antibody 
staining revealed that the majority of RS rearrangements most 
likely occurred toward the end of this period (  Fig. 2 b  ). 
  In the subsequent developmental subset, Fr. E (newly 
formed IgM  +   immature B cells), V    -RS rearrangement levels 
were reduced by threefold and were closer to those of mature, 
circulating B cells (Fr. F). The diff  erence in V    -RS rearrange-
ment levels between Fr. D cells and       +   Fr. E cells could be 
Most importantly, RS rearrangements do not encode a func-
tional protein (  10  ) and, therefore, are independent of antibody 
specifi  city, making their measurement potentially applicable 
to any disease in which B cells play a pathogenic role. By 
combining a quantitative PCR assay for RS rearrangement 
frequency with cell sorting, receptor editing can be analyzed 
in diff  erent B cell subsets (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20082053/DC1). 
  We analyzed the most abundant class of RS rearrange-
ments, which are V     to RS in mice and intron RS (iRS) to 
RS in humans (  23, 24  ). For the human studies, iRS to RS 
rearrangements were quantifi  ed relative to an absolute stan-
dard consisting of a cloned iRS-RS rearrangement that was 
serially diluted in fi  broblast DNA. Log-linear amplifi  cation 
was observed over the range of 0.7  –  200% RS rearrangements 
per cell genome (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20082053/DC1). 200% corresponds to 
having two RS rearrangements, one on each      allele. Typical 
RS frequency measurements fall within this log-linear range. 
For the mouse studies, a degenerate V     primer was used for 
RS rearrangement measurements (  25  ). Mouse V    -RS rear-
rangements were quantifi   ed as fold diff  erence  relative  to 
IgM  +  ,       +   spleen DNA from B6 mice (the spleen contains a 
mixture of diff  erent V    s). Fold diff  erences were used rather 
than absolute frequencies to avoid confusion caused by dif-
fering amplifi  cation effi   ciencies for diff  erent V     genes. 
  The correlation between RS rearrangement and extensive 
light chain rearrangement has been established in earlier works 
from several groups (  8, 9, 23, 24, 26, 27  ). Consistent with 
these earlier studies, RS rearrangement is increased eightfold 
among       +   mouse IgM  +   B cells compared with       +   cells (  Fig. 1 b  ). 
Among CD19  +   human B cells, 16% of       +   B cells carried an 
RS rearrangement, and the frequency of RS rearrangements 
among       +   B cells was   >  100%, indicating that some       +   B cells 
have rearranged to RS on both      alleles. Because RS levels are 
higher in       +   than in       +   B cells, the overall RS rearrangement 
frequency correlates inversely with the     /     ratio. To reduce 
the variability in RS frequency measurements introduced by 
the     /     ratio, RS analysis was performed separately in       +   or 
      +   cells. However, it is important to note that RS rearrange-
ment levels in a given       +   or       +   B cell population vary inde-
pendently from the overall     /     ratio (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20082053/DC1; 
and see Fig. S5 a). Thus, measuring the RS frequency is not 
simply a cumbersome method for assessing the     /     ratio. Also 
of note, RS rearrangement frequencies are correlated in     - 
and     -expressing B cells within single individuals (this intrain-
dividual correlation and the concept of an RS set point will be 
addressed in the analysis of human subjects that follows). 
  RS rearrangement levels vary between developmental 
and functional B cell subsets in mice 
  If RS rearrangement is a marker of ongoing antibody light 
chain rearrangement, it should occur at the time of late      or 
     rearrangement. Consistent with this prediction, the highest 
level of RS rearrangement was found among bone marrow 
    Figure 2.         RS rearrangement levels are highest in late pre  –  B cells.  
(a) V    -RS rearrangement levels quantifi  ed in bone marrow subsets from 
C57BL/6 mice (  n   = 5). (b) V    -RS rearrangement levels assayed in less ma-
ture (BP-1  +  ; gray bar) and more mature (BP-1       ; black bar) Fr. D B cells of 
C57BL/6 mice (  n   = 3). All PCR reactions were performed in duplicate. Data 
are depicted as fold difference (+SEM; **, P   ≤   0.01) relative to the mean 
RS level in C57BL/6 splenic B220  +   IgM +      +   B cells (dashed lines). Bone 
marrow B cell fractions were obtained by fl  ow cytometry, as shown in Fig. 
S1 (available at http://www.jem.org/cgi/content/full/jem.20082053/DC1).     2988 RS REARRANGEMENT AS A MARKER OF RECEPTOR EDITING   | Panigrahi et al. 
ceptor editing, a twofold increase in RS rearrangement levels 
was observed in IgM  a+   B cells (  Fig. 3 b  ). 
  Mouse strains prone to autoimmunity display lower levels 
of RS rearrangement 
  The preceding experiments established the developmental 
timing of RS rearrangement and documented a positive cor-
relation between RS rearrangement frequency and an auto-
reactive antibody heavy chain in inbred mice. To determine 
if RS rearrangement is altered in the context of autoimmu-
nity, we measured RS rearrangement frequency in two dif-
ferent mouse models of autoimmune disease, MRL/lpr mice 
as a model of SLE and nonobese diabetic (NOD) mice as a 
model of T1D. We observed decreases in RS rearrangement 
levels among Fr. D cells of both MRL/lpr (2.5-fold reduc-
tion; P   <   0.05) and NOD (3.7-fold reduction; P   <   0.01) 
mice when compared with C57BL/6 mice (  Fig. 4 a  ).   Inter-
estingly, fewer RS rearrangements were also observed among 
Fr. E cells in both MRL/lpr and NOD mice relative to 
C57BL/6 mice. This decrease was evident in the mature re-
circulating B cells of the bone marrow (Fr. F) as well, imply-
ing that unedited or minimally edited cells persisted through 
development. Measurement of RS levels in splenic B cell 
subsets further substantiated this fi  nding (  Fig. 4 b  ). 
  To determine if the lower levels of V    -RS rearrange-
ments detected in MRL/lpr and NOD mice are attributable 
to strain eff  ects, rather than as consequences of an autoim-
mune state, RS levels were measured in MRL/MpJ mice, 
which share the same genetic background as MRL/lpr mice 
but lack the   Fas   mutation that is responsible for their lym-
phocytosis and accelerated systemic autoimmunity. Similarly, 
NOD mice were compared with nonobese resistant (NOR) 
caused by the inclusion of pre  –  B cells undergoing or complet-
ing      rearrangement within Fr. D. However, RS levels in to-
tal IgM  +   Fr. E cells were similar to       +   Fr. E cells, suggesting 
that exclusion of       +   cells from Fr. E cannot fully account for 
the decrease. Death of RS  +   cells or their rapid exit from the 
bone marrow to a peripheral pool may contribute to the de-
crease in RS rearrangement levels in Fr. E relative to Fr. D. 
  RS rearrangement levels differ between autoreactive 
and nonautoreactive B cells 
  It is unclear from the preceding experiments how or if RS re-
arrangement frequency is linked to autoreactivity. Editing is 
driven either by the potential of the antibody heavy light 
chain pair to form autoantibodies (active model), or it occurs 
without regard for receptor specifi  city (passive model). To 
distinguish between active and passive editing, RS rearrange-
ment frequencies were analyzed in the 56R mouse model, 
where the B cell repertoire has been characterized extensively 
(  29  –  31  ). The 56R mouse carries a site-directed transgene 
encoding an anti-DNA  –  specifi   c Ig heavy chain. Using 
B6.56R  +/      mice, one can distinguish B cells with an autoreactive 
Ig heavy chain (IgM  a+  , mostly 56R expressing) and endogenous 
(IgM  b+  , 56R       ) B cells (  Fig. 3 a  ).   56R-expressing B cells have 
a restricted light chain repertoire consisting of only a handful 
of light chains, termed editors, because they modify or reduce 
DNA binding (  29  –  31  ). This restriction in light chain usage 
could arise if 56R B cells with noneditor light chains were 
counterselected or if B cells with noneditor light chains were 
subjected to more receptor editing. The former alternative 
predicts equal levels of RS rearrangement in IgM  a+   and IgM  b+   
cells, whereas the latter predicts higher levels of RS rearrange-
ment in IgM  a+   B cells. Consistent with an active model of re-
    Figure 3.         RS rearrangements are increased in B cells expressing an autoreactive heavy chain in self-tolerant mice.   (a) Flow cytometry of splenic 
follicular (B220  + ,  AA4.1     ,  CD23 + )     +   B cells from heterozygous B6.56R mice depicting separation of B cells by Ig heavy chain allotype (percentages are 
given in the gated regions). (b) V    -RS rearrangement frequencies measured in follicular B cells expressing endogenous heavy chains (IgM  b+  ; black bar) and 
the 56R anti-DNA heavy chain (IgM  a+  ; gray bar) from heterozygous B6.56R mice (  n   = 4). All PCR reactions were performed in duplicate. Data are presented 
as fold difference (+SEM; *, P   <   0.05 by a one-tailed Student  ’  s   t   test) relative to the mean RS level in C57BL/6 splenic B220  +   IgM +      +   B cells (dashed line).     JEM VOL. 205, December 22, 2008 
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tively;   Fig. 5 c  ). Additionally, linear regression analysis re-
vealed a lower degree of RS rearrangement in       +   cells relative 
to levels in       +   cells in patients with autoimmune disease 
compared with healthy controls. Collectively, these fi  ndings 
suggest that some SLE and T1D patients have lower editing 
set points than those of most healthy individuals. 
    DISCUSSION   
  The development of assays to monitor B cell tolerance and se-
lection stringency can inform the choice of B cell  –  targeted 
therapy for autoimmune disease. This contention is based on 
the idea that individual patients with SLE and T1D have diff  er-
ent tolerance defects (  33, 34  ). Previous assays that monitor B 
cell tolerance are problematic because they tend to measure rel-
atively late events, such as autoantibody production, rather than 
the pathways that B cells take on their way to becoming auto-
immune. The RS rearrangement assay presented in this paper 
takes 2 d to perform and provides insights into central (early) B 
mice, which share the same diabetogenic MHC haplotype 
(H2  g7  ) with NOD mice but are insulitis resistant and do not 
develop T1D (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20082053/DC1) (  32  ). These   “  control  ”   strains 
share the propensity to develop autoimmunity with MRL/
lpr and NOD mice but do so at a much slower pace. The 
control mice were analyzed at 3 mo of age, a time at which 
autoimmune pathology is not yet apparent. Although RS re-
arrangement levels were slightly increased among some bone 
marrow B cell subsets in the control mouse strains, levels in 
mature B cells were comparable in MRL/MpJ and NOR 
mice to their more autoimmune counterparts. The low fre-
quency of RS rearrangement in MRL/MpJ and NOR mice 
suggests that a reduced level of receptor editing predisposes 
toward the development of autoimmunity rather than arising 
as a consequence of autoimmune disease. 
  RS rearrangement levels are lower in human SLE and T1D 
  To further investigate the level of receptor editing in the 
context of defective tolerance, we compared RS rearrange-
ment levels in peripheral B cells from human subjects with 
established disease (SLE or T1D) to healthy control subjects 
(see Materials and methods). For this analysis, we evaluated 
26 control subjects, 24 patients with SLE, and 25 patients 
with T1D. Demographic features of the subject groups were 
compared, and no signifi  cant diff  erences were observed be-
tween control and SLE groups with respect to age, gender, 
and race; however, the T1D group contained a larger pro-
portion of men and Caucasians than the control and SLE 
groups (  Table I  ).   Nonetheless, RS frequencies were not cor-
related with subject age, gender, or race (Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20082053/DC1). 
  Among CD19  +         +   B cells, RS rearrangement frequencies 
from SLE patients were lower on average compared with 
levels from healthy controls (P   <   0.01;   Fig. 5 a  ).   The RS 
rearrangement frequency in       +   B cells from T1D was not 
signifi  cantly decreased compared with control subjects. In 
CD19  +         +   B cells, RS levels were lower in both SLE and 
T1D patients compared with control subjects (P   <   0.01;   Fig. 
5 b  ). These results resemble those from the autoimmune 
mouse models and suggest that lower levels of RS rearrange-
ment may be correlated with disease susceptibility. 
  We chose the bottom 10th percentile of the normal pop-
ulation as an arbitrary cutoff   for the RS rearrangement fre-
quency distribution in       +   B cells (    RS). Using this cutoff  , 
the fraction of subjects with a low     RS value is 2 out of 26 
for the healthy control subjects, 13 out of 24 for SLE, and 8 
out of 25 for T1D. Using a similar     RS cutoff  , 3 out of 26 
controls, 9 out of 23 SLE patients, and 11 out of 25 T1D pa-
tients had low RS levels. Additionally, RS levels were low in 
both       +   and       +   B cells in 7 out of 23 SLE and 7 out of 25 
T1D patients, indicating that subjects with low     RS levels 
tended to also have low     RS levels. Indeed, Spearman cor-
relations between the     RS and     RS measurements were sig-
nifi  cant in both healthy subjects and patients with autoimmune 
disease (r = 0.54, P   <   0.01 and r = 0.52, P   <   0.01, respec-
    Figure 4.         Autoimmune-prone mouse strains display reduced levels 
of RS rearrangement.   (a)  V   -RS rearrangement levels in bone marrow 
subsets of MRL/lpr mice (white bars;   n   = 4) and NOD mice (gray bars;   n   =  5). 
Data from C57BL/6 mice are included for comparison. (b) V   -RS  rearrange-
ment levels in     +   splenic B cell subsets from C57BL/6 (black bars;   n   =  5), 
MRL/lpr (white bars;   n   = 4), and NOD (gray bars;   n   = 5) mice. All PCR 
reactions were performed in duplicate. Data are represented as fold dif-
ference (+SEM; *, P   <   0.05 and **, P   <   0.01) relative to the mean RS level 
in C57BL/6 splenic B220  +   IgM +      +   B cells (dashed lines).     2990 RS REARRANGEMENT AS A MARKER OF RECEPTOR EDITING   | Panigrahi et al. 
  The current study demonstrates decreases in RS rearrange-
ment frequency in mouse models of SLE and T1D. Both 
MRL/lpr and NOD mice exhibited lower RS levels com-
pared with wild-type C57BL/6 mice. The fi  nding of lower 
editing levels in MRL/lpr mice is consistent with recent work 
from Lamoureux et al. demonstrating decreased receptor edit-
ing in response to a ubiquitous membrane-bound self-antigen 
in transgenic MRL/lpr mice (  43  ). The fi  nding of decreased 
RS rearrangement in NOD mice is at odds with a previous re-
port in which editing was measured using a membrane-bound 
facultative self-antigen (hen egg lysozyme) (  44  ). The RS assay, 
however, does not focus on one kind of self-antigen. 
  Although both MRL/lpr (  45  ) and NOD (  46  ) strains har-
bor previously characterized defects in apoptosis, lower RS 
levels were not linked to these defects per se, as B cells from 
MRL/MpJ and NOR mice (both with intact apoptosis) also 
exhibited lower RS levels. In the case of MRL/lpr mice, the 
additional defect conferred by the   lpr   mutation (  45  ) may lead 
to less stringent selection of minimally edited immature B 
cells. Similarly, the fi  nding of low RS rearrangement levels in 
both the NOD and NOR strains suggests that a second toler-
ance defect present only in NOD mice is required for devel-
opment of diabetes. However, the genetic backgrounds of 
these control strains predispose them to develop autoimmu-
nity. Despite having an intact   Fas   gene, MRL/MpJ mice 
spontaneously develop autoimmunity, including pancreatitis 
(  47  ) and glomerulonephritis (  48  ), but the disease is milder 
and occurs later in life. NOR/LtJ mice share the diabeto-
genic H2  g7   haplotype with NOD mice and have altered mac-
rophage and peripheral T cell compartments (  32  ). All of the 
mice used for these experiments were 3 mo of age, which is 
at a time that precedes disease development in NOR and 
MRL/MpJ mice. Collectively, these fi  ndings suggest that de-
creased RS rearrangement levels in these mice refl  ect an al-
tered propensity to develop autoimmunity. 
  In humans, lower RS rearrangement levels were also de-
tected in both SLE and T1D patients compared with healthy 
control subjects. The decrease was most apparent in       +   B cells, 
but the level of RS rearrangement was correlated in       +   and       +   
cell tolerance. Furthermore, it can be combined with immuno-
phenotyping to analyze editing levels in diff  erent peripheral B 
cell subsets. As such, it may be possible in the future to use this 
assay to monitor and stage defects in B cell tolerance. 
  The RS rearrangement assay gives an estimate of the 
overall level of light chain rearrangement in a defi  ned popu-
lation of B cells. The correlation between RS level and the 
light chain rearrangement level is based on earlier studies 
documenting that 10  –  15% of mouse       +   splenic B cells had 
undergone RS recombination, whereas virtually all       +   splenic 
B cells harbored an RS rearrangement (  23, 26, 27  ). Similarly, 
studies of single human B cells and acute lymphoblastoid leu-
kemia cell lines demonstrated that cells expressing      harbored 
more RS rearrangements than ones that expressed      (  24, 35  ). 
Furthermore,      B cells took     24 h longer to label with BrdU 
than B cells with      rearrangements (  36  ). Finally, studies in B 
cell leukemia cell lines subjected to Bcr-Abl tyrosine kinase 
blockade exhibited temporally ordered light chain rearrange-
ments:      followed by RS followed by      (  21  ). The current 
study is consistent with all of these previous studies: RS rear-
rangement frequencies were higher in       +   B cells than in       +   B 
cells and were most frequent in late pre  –  B cells (Fr. D). Every 
other B cell subset, including Fr. E (which is where surface 
antibody is fi  rst detected) and more mature splenic B cells, 
exhibited lower RS levels. As RS rearrangements are nonre-
vertible, these fi  ndings suggest that receptor editing fails to 
salvage some of the most highly edited B cells from clonal 
deletion. An increased RS rearrangement frequency was also 
observed in B cells with autoreactive heavy chains. Because 
RS rearrangements do not encode a protein that can be se-
lected, this result indicates that the presence of an autoreac-
tive heavy chain increases the likelihood of ongoing light 
chain rearrangement and is consistent with other reports fa-
voring an active, autoantigen-driven model of receptor edit-
ing (  37, 38  ). These fi  ndings are consistent with earlier work 
in autoantibody transgenic and knock-in mice showing that 
some highly edited B cells are auto-/multireactive (  39  –  42  ). 
The loss of B cells with more RS rearrangements could also 
refl  ect the failure to produce a functional antibody. 
    Table I.        Demographic comparison among subject groups 
Control SLE T1D
Number of subjects 26 24 25
Average age (yr) 33.8 (22  –  52) 37.3 (21  –  55) 38.5 (19  –  69)
Female (%)    a   0.88 0.88 0.56
Caucasian (%)    a   0.58 0.29 0.92
African-American (%) 0.27 0.42 0.04
Other (%) 0.15 0.29 0.04
Mean     /     ratio (CD19  +  ) 1.5 (1.1  –  2.3) 1.8 (1  –  4) 1.6 (0.8  –  2.4)
Mean B cell fraction (CD19  +  ) 0.11 (0.05  –  0.19) 0.1 (0.01  –  0.2) 0.1 (0.02  –  0.19)
Mean absolute B cell count (per   μ  l)    b   221    ±   126 176   ±   163 190   ±   107
  a Signifi  cant differences were found with respect to gender and race between the T1D and control groups (P   <   0.05 and P   <   0.01, respectively) as well as between the T1D and 
SLE groups (P   <   0.05 and P   <   0.001, respectively).
  b  Absolute B cell counts were obtained by multiplying the WBC count (from the complete blood count) by the percentage of lymphocytes (from the electronic differential) and 
by the CD19  +   fraction, and are listed as means   ±   SD. Absolute B cell counts represent the average of 25 control subjects, 23 SLE patients, and 24 T1D patients, respectively.JEM VOL. 205, December 22, 2008 
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B cells in individual patients. The levels were not proportional 
to the     /     ratio or to the fraction of B cells in the blood. 
These fi   ndings have theoretical and practical implications. 
The theoretical implication is that individuals may have diff  er-
ent RS rearrangement   “  set points.  ”   The set points tend to be 
lower in T1D and SLE than in healthy subjects but overlap to 
some degree. It will be important to directly measure RS lev-
els in diff  erent peripheral B cell subsets and determine if dif-
ferences can be correlated with B cell selection checkpoints or 
if, in a fashion similar to the mouse models, diff  erent subsets 
will show correlated RS levels. Until now, selection check-
points have been monitored by single-cell antibody cloning 
and expression studies (  1, 49, 50  ). If RS rearrangement can be 
used instead, it may be possible to more easily defi  ne B cell 
tolerance checkpoints in individual patients with autoimmune 
disease. The practical implication of having correlated RS re-
arrangement frequencies in       +   and       +   B cells is that it may be 
possible to measure RS rearrangement frequency in whole 
blood rather than in sorted B cell subsets and then to correct 
the measurement for the B cell fraction and     /     ratio. 
  Given the concordance of RS rearrangement levels in 
T1D and SLE, we considered the possibility that upstream ge-
netic defects could decrease receptor editing in both disorders. 
One candidate is protein tyrosine phosphatase nonreceptor 22 
(PTPN22; also known as Lyp). PTPN22 is a lymphoid-spe-
cifi  c phosphatase that suppresses T cell activation (  51  ). A vari-
ant of PTPN22 (R620W) is common in both SLE and T1D 
(  52, 53  ) and appears to have a more active phosphatase in the 
setting of T1D (  54  ). Although the eff  ects of PTPN22 R620W 
are not yet well defi  ned in B cells (  55  ), one is tempted to 
speculate that there could be an increased BCR signaling 
threshold caused by PTPN22 R620W that would result in 
decreased receptor editing. Other potential candidates include 
RAG or molecules that infl  uence the intracellular localization 
or expression of RAG, such as the nuclear importin KPNA1 
(  56  ), IFN regulatory factor 4 (  57  ), or the transcription factor 
Foxo1 (  58, 59  ). Because RS rearrangement frequency corre-
sponds to a phenotype rather than a heritable genetic altera-
tion, there could be several diff  erent defects, each of which 
could contribute independently to a low RS frequency. 
  It is not yet clear what the biological consequences are of 
a low RS rearrangement frequency or if the lowest levels of 
RS rearrangement are inherently the most dangerous. Per-
haps individuals with low RS levels (including a small subset 
of currently healthy subjects) are at increased risk of develop-
ing autoimmunity. In this regard, the prospective analysis of 
fi  rst-degree relatives of patients with autoimmunity might be 
especially informative. It will also be important to fi  nd out 
how generalizable the RS rearrangement frequency is to 
    Figure 5.         RS rearrangement levels are lower among SLE and T1D 
patients.   (a and b) iRS rearrangement frequencies as quantifi  ed in pe-
ripheral CD19  +   9G4          +   and  CD19 +   9G4          +   B cells, respectively. Data 
represent the iRS levels in healthy control subjects (black circles;   n   =  26), 
SLE patients (white squares;   n   = 24 for     +   and   n   = 23 for     +  ), and T1D 
patients (gray triangles;   n   = 25). Mean values are depicted as horizontal 
lines. The 10th percentile of iRS frequencies among control subjects is 
depicted as a dashed line. (c) iRS rearrangement frequencies in CD19  +  
9G4           +   peripheral B cells compared with frequencies in CD19  +   9G4          +  
cells from healthy controls (black circles;   n   = 26) and SLE and T1D pa-
tients (white squares;   n   = 48). All PCR reactions were performed in du-
plicate. Data are depicted as iRS rearrangement frequency per genome 
copy. Trend lines are depicted for control patients (continuous line; 
slope = 5.4) and autoimmune patients (dashed line; slope = 3.3; r-values 
indicate Spearman correlation coeffi  cients; **, P   <   0.01).     
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with elevated levels of autoantibodies to GAD65. Subjects meeting these crite-
ria but presently receiving immunosuppression drugs to support a kidney, pan-
creas, or islet cell transplant were excluded. The study protocol was approved 
by the Institutional Review Board of the University of Pennsylvania, and all 
subjects gave their written informed consent to participate. 
  Statistical analysis.     Group comparisons for the mouse experiments were 
performed with a two-tailed Student  ’  s   t   test unless otherwise specifi  ed. Group 
comparisons in human subjects were performed via one-way analysis of vari-
ance followed by a two-tailed Student  ’  s   t   test. Correlation analyses were per-
formed by calculating Spearman  ’  s rank correlation coeffi   cients. Categorical 
data (gender and race) comparisons were analyzed using Fisher  ’  s exact test. 
For all tests, P   ≤   0.05 was considered signifi  cant. 
  Online supplemental material.     Fig. S1 depicts fl  ow cytometric analysis of 
mouse and human B cell populations isolated for RS quantitation. Fig. S2 
describes the absolute quantifi  cation method used to monitor iRS-KDE rear-
rangements via real-time PCR. Fig. S3 demonstrates that RS rearrangement 
levels among       +   B cells are independent of     /     ratios. Fig. S4 depicts RS re-
arrangement levels in MRL/MpJ and NOR mouse strains. Fig. S5 demon-
strates that diff  erences in iRS rearrangement levels among subject groups do 
not correlate with demographic diff  erences. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20082053/DC1. 
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other autoimmune diseases as a potential marker for defective 
central tolerance. 
  MATERIALS AND METHODS 
  Mice.     B6.56R mice have been described previously (  30  ). C57BL/6, NOD, 
NOR, MRL/lpr, and MRL/MpJ mice were obtained from the Jackson 
Laboratory. All animal experiments were performed on 3  –  4-mo-old mice in 
accordance with protocols approved by the University of Pennsylvania 
School of Medicine Animal Care and Use Committee. 
  Flow cytometry.     Mouse cell suspensions were prepared from femurs, tib-
ias, and spleens in FACS buff  er (PBS, 0.5% BSA, 0.01% NaN  3  , 1 mM 
EDTA) after hypotonic RBC lysis (ACK Lysing Buff  er; BioWhittaker). 
B cell populations were defi  ned as described in Fig. S1. Because of poor reac-
tivity of AA4.1 antibodies in NOD and NOR mice (  60  ), bone marrow and 
peripheral subsets in these mice were defi  ned using a method that has been 
described previously (Fig. S1) (  61  ). Human B cells were isolated from whole 
blood using Lymphocyte Separation Medium (MP Biomedicals) followed by 
resuspsension in FACS buff  er. Mouse lymphocytes were stained using anti  –
  IgM-PE-Cy7 (II/41), anti  –  IgD-PE (11-26), anti  –  B220-allophycocyanin 
(APC)-AF750 (RA3-6B2; eBioscience), and anti  –  Ig    -FITC (187.1), anti  –
  BP-1  –  FITC (6C3), anti  –  CD43-PE (S7), anti  –  CD23-PE (B3B4), and anti  –
  AA4.1-APC (BD). Human lymphocytes were stained with anti –  CD19  –  Pacifi  c 
blue (Invitrogen) and anti  –  Ig    -FITC, anti  –  CD27-FITC, anti  –  Ig    -PE, and 
anti  –  CD38-PE-Cy7 (BD). To maximize effi   cient use of patient samples for 
additional experiments not described in this paper, CD19  +   B cells marked by 
the antiidiotypic monoclonal antibody 9G4 (provided by M. Sanders, Palin-
gen, Inc., Palo Alto, CA), which recognizes V  H  4-34 heavy chain rearrange-
ments (  62  ), were excluded from the human CD19  +   B cell populations 
described (Fig. S1 d). 9G4Id  +   cells comprised 5.1%, 5.7%, and 4.2% of total 
CD19  +   B cells from control, SLE, and T1D subjects, respectively. All cells 
were sorted using a FACSAria (BD), with sort purities   >  90%. 
  Quantitative PCR.     Genomic DNA was isolated from sorted B cells using 
the Gentra Puregene Tissue Kit (QIAGEN). Quantitative PCR (40  °  C for 
10 min, 95  °  C for 10 min, followed by 60 cycles at 95  °  C for 10 s, 60  °  C for 30 s, 
and 72  °  C for 1 s) was performed on 15  –  50-ng template DNA in a 20-  μ  l reac-
tion mix containing 1  ×   LightCycler 480 Probes Master Mix (Roche), 0.5 U 
LightCycler Uracil-DNA Glycosylase (Roche), 0.5   μ  M of a forward primer, 
0.5   μ  M of a reverse primer, and 0.2   μ  M of a hydrolysis probe using a Light-
Cycler 480 real-time PCR system (Roche). Primers and probes are described 
in Fig. S2. The amount of V    -RS product in each mouse sample was nor-
malized to the amount of     -actin product and compared with the normalized 
target value in wild-type C57BL/6 B220  +   IgM  +         +   splenocytes to determine 
a relative quantity (comparative C  T   [DDC  T  ] method). The frequency of iRS-
KDE rearrangements in each human sample was determined via absolute 
quantifi  cation using a standard curve generated by serial dilution of a cloned 
iRS-KDE rearrangement resuspended with 100 ng of human fi  broblast DNA 
(Fig. S2). To determine the number of genome copies,     -actin was measured 
via absolute quantifi  cation using a standard curve consisting of serially diluted 
human fi  broblast DNA. Reactions were performed in duplicate, and samples 
with inconsistent replicates or     -actin cycle numbers   >  35 were excluded. 
  Human subjects.     Volunteer healthy adult subjects with no history of autoim-
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